Critical Therapeutics and Dey launch COPD therapy

Critical Therapeutics and Dey have entered into an agreement for the co-promotion of inhalation product Perforomist, indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as chronic obstructive pulmonary disease (COPD). Under the agreement, Critical Therapeutics has agreed to provide a minimum number of product details each month to a targeted group of physicians.

Dey will pay Critical Therapeutics a co-promotion fee under a calculation based on retail sales above a pre-specified forecast of Perforomist, which will be available nationwide through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies.